Characterizing the Journey of Early Alzheimer’s Disease in Patients Initiating Lecanemab Treatment in the United States: A Real-World Evidence Study
Abstract Introduction With the advent of disease-modifying therapies for early Alzheimer’s disease (AD), a comprehensive characterization of patients initiating lecanemab in the USA is needed to understand its use in real-world settings. Methods This retrospective observational study used administra...
Saved in:
| Main Authors: | Marwan N. Sabbagh, Chenyue Zhao, Malena Mahendran, Se Ryeong Jang, François Laliberté, Hideki Toyosaki, Kaixin Zhang, Feride Frech, Kavita V. Nair |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-05-01
|
| Series: | Neurology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40120-025-00756-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Advancements in Early Alzheimer’s Treatment: Narrative Review about Lecanemab (Leqembi ®)
by: Adrianna Muciek, et al.
Published: (2024-12-01) -
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
by: Taha basit Ameen, et al.
Published: (2025-05-01) -
Lecanemab in clinical practice: real-world outcomes in early Alzheimer’s disease
by: Noa Bregman, et al.
Published: (2025-05-01) -
A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases
by: Haoxiang Hu, et al.
Published: (2025-04-01) -
Two cases of Amyloid-Related Imaging Abnormalities (ARIA) following lecanemab treatment for alzheimer’s disease and a literature review
by: Yingte Wang, et al.
Published: (2025-07-01)